相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1997
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Biofrontera Inc. reported second quarter 2026 net product revenue of $12.0 million, a 32.9% increase over the prior-year period, driven by Ameluz unit volume growth and a price increase. - Gross margin improved to 80% from 71% year over year, reflecting the lower Ameluz cost structure established after the strategic transaction with Biofrontera AG. - The company has a PDUFA date in late September 2026 for Ameluz in superficial basal cell carcinoma, which would make it the first PDT approved in the U.S. for cancerous tumors. - Positive Phase III results in actinic keratosis on the extremities, neck, and trunk, plus encouraging Phase 2B acne data, support expansion of the PDT platform.
- The Patent Trial and Appeal Board ruled that Sun Pharmaceutical's patent claims for an adjustable illuminator used in photodynamic therapy are unpatentable as obvious over existing prior art. - Biofrontera companies successfully challenged Sun Pharmaceutical's illumination device patent, which relates to uniform light distribution for treating conditions like actinic keratosis. - In a separate case, Illumina successfully invalidated Molecular Loop Innovations' patent claims for nucleic acid template integrity methods in multiplex sequencing reactions. - These patent decisions underscore ongoing intellectual property challenges in medical device and genomic sequencing technology development.
- Biofrontera Inc. has acquired full U.S. rights to Ameluz® and RhodoLED® from former parent Biofrontera AG, including the New Drug Application and all intellectual property. - The new earnout structure reduces payment rates to 12-15% of U.S. net sales from the previous 25-35%, expected to accelerate the company's path to profitability. - The $11 million transaction was funded by existing investors Rosalind Advisors and AIGH Capital Management, with the final $2.5 million released upon closing. - Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory oversight, and commercialization of the photodynamic therapy products in the United States.
- Biofrontera Inc. acquired all US assets for Ameluz® and RhodoLED® from Biofrontera AG, including the New Drug Application and associated patents. - The company secured $11 million in financing led by Rosalind Advisors and AIGH Capital Management to fund the acquisition and operations to profitability. - Royalty rates were dramatically reduced from 25-35% to 12% of net sales (15% above $65 million revenue), providing significant cost savings. - The transaction grants Biofrontera Inc. full control over manufacturing, regulatory, and commercial responsibilities for its photodynamic therapy products in the US market.
- Biofrontera Inc. and Biofrontera AG are negotiating potential company combination or license agreement adjustments that could transfer rights and reduce transfer pricing for US products. - The discussions may result in fundamental changes to the cooperation between the US subsidiary and German parent company, though no definitive terms have been established. - Biofrontera Inc. specializes in photodynamic therapy for dermatological conditions, commercializing Ameluz with RhodoLED devices for treating actinic keratosis and conducting trials for skin cancers and acne.
- Biofrontera Inc. has secured FDA approval for a reformulated Ameluz nanoemulsion gel, extending patent protection until 2043 and allowing up to three tubes per treatment, potentially increasing revenue through larger average sales. - The company's successful Phase III study for Ameluz in treating superficial basal cell carcinoma positions it for treatment expansion beyond actinic keratosis, with clinical trials also targeting moderate-to-severe acne. - A strategic restructuring agreement with Biofrontera's former parent company has reduced the transfer price of Ameluz from 50% to 25%, significantly enhancing gross margins and improving the path to profitability.
